Wyeth has received FDA approval for Pristiq (desvenlafaxine) for the treatment of adult patients with major depressive disorder (MDD).Pristiq, a once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), is expected to be available in May 2008.

For more information call (800) 934-5556 or visit www.pristiq.com.